Pirkanmaan hyvinvointialue

The trials here

What the 31 trials at this site are about, from their registry records.

Conditions

• Childhood cancers14 trials
• Coeliac disease4 trials
• Acute lymphoblastic leukaemia3 trials
• Acute myeloid leukaemia3 trials
• Sarcoma3 trials
• Kidney cancer2 trials
• Lung cancer2 trials
• Ovarian cancer2 trials
• Prostate cancer2 trials
• Coronary artery disease1 trial
• Dystonia1 trial
• Endometrial cancer1 trial
• and 7 more

Phase

• Phase 318 trials
• Phase 26 trials
• Phase 2/33 trials
• Phase 12 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Recruiting15 trials
• Completed8 trials
• Not yet recruiting5 trials
• Active, not recruiting3 trials

Lead sponsor

• Boehringer Ingelheim2 trials
• Gustave Roussy, Cancer Campus, Grand Paris2 trials
• Pirkanmaan hyvinvointialue2 trials
• Teva Branded Pharmaceutical Products R&D LLC2 trials
• The University Of Birmingham2 trials
• and 21 more

Running trials

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Susanna Vuorenoja

• Not yet recruiting

  Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis

  NCT07646223· Phase 2· Tampere University Hospital· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· Phase 3· Genmab A/S· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033

  2024-520409-38-00· Phase 1· First Tracks Biotherapeutics Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

  NCT06807463· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Recruiting

  CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

  NCT06262438· Phase 2· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)

  2023-504999-25-00· Phase 3· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source

• Recruiting

  Measuring Oncological Value of Exercise and Statin (MOVES)

  2024-515109-24-00· Phase 3· Pirkanmaan hyvinvointialue· Source

• Recruiting

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

  NCT05476939· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.

  2024-510578-25-00· Phase 3· The University Of Birmingham· Source

• Active, not recruiting

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· University of Birmingham· Source

• Recruiting

  A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

  NCT04307576· Phase 3· Mats Heyman· Source

• Active, not recruiting

  Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147· Phase 3· Children's Oncology Group· Source

• Recruiting

  SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

  NCT02265770· Phase 2/3· Centre Leon Berard· Source

• Recruiting

  rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

  2024-516078-31-00· Phase 2/3· The University Of Birmingham· Source

• Active, not recruiting

  International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

  NCT02066220· Phase 2/3· Universitätsklinikum Hamburg-Eppendorf· Source

• Recruiting

  NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years

  NCT01828489· Phase 3· Vaestra Goetalandsregionen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• Acute myeloid leukaemia3 recruiting
• Sarcoma3 recruiting
• Ovarian cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Coeliac disease1 recruiting
• Endometrial cancer1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Neuroendocrine tumours1 recruiting
• Prostate cancer1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Active, not recruiting

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Active, not recruiting

  A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

  NCT06557772· Phase 2· Sanofi· Source

• Completed

  A Phase 1b Study to Characterize the Safety and Tolerability of TEV-53408 in Adults with Celiac Disease

  2022-502817-27-00· Phase 1· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  Selän alueen poikkeava aktiivisuus servikaalisessa dystoniassa

  2024-517068-43-00· Phase 4· Pirkanmaan hyvinvointialue· Source

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

  NCT05565378· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

  NCT03937219· Phase 3· Exelixis· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Recruiting

  International Study for Treatment of High Risk Childhood Relapsed ALL 2010

  NCT03590171· Phase 2· Charite University, Berlin, Germany· Source